A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5458-5466

  Meng, Xiangjun ^a   Leyva, Mili L ^a   Jenny, Marjorie ^a   Gross, Isabelle ^a   Benosman, Samir ^a   Fricker, Bastien ^a   Harlepp, Sébastien ^b   Hébraud, Pascal ^b   Boos, Anne ^c   Wlosik, Pauline ^a   Bischoff, Pierre ^a   Sirlin, Claude ^a   Pfeffer, Michel ^a   Loeffler, Jean Philippe ^a   Gaiddon, Christian ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE PHYSIQUE ET CHIMIE DES MATÉRIAUX DE STRASBOURG   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; ORGANOMETALLIC COMPOUND; PROTEIN DISULFIDE ISOMERASE; RNA; RUTHENIUM DERIVED COMPOUND 11; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; SENSORY NERVE CELL; TRANSCRIPTION INITIATION; TUMOR GROWTH;

EID: 67650456858     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4408     Document Type: Article

References (50)

1. Bruijnincx PC, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 2008;12:197-206.
2. Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK. Antitumour metal compounds: more than theme and variations. Dalton Trans 2008:183-94.
3. Dyson PJ, Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans 2006:1929-33.
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
5. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol 2007;20:719-25.
6. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003;2:597-607.
7. Allardyce CS, Dyson PJ. Rutheniumin medicine: current clinical uses and future prospects. Platinum Metals Rev 2001;45:62.
8. Anghileri LJ. The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calciumin the tumor. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1975;83:213-7.
9. Giraldi T, Sava G, Bertoli G, Mestroni G, Zassinovich G. Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloroplatinum(II). Cancer Res 1977;37:2662-6.
10. Sava G, Giraldi T, Mestroni G, Zassinovich G. Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma. Chem Biol Interact 1983;45:1-6.
11. Keppler BK, Balzer W, Seifried V. Synthesis and antitumor activity of triazolium-bis(triazole)-tetrachlororuthenate (III) and bistriazolium- triazolepentachlororuthenate (III). Two representatives of a new class of inorganic antitumor agents. Arzneimittelforschung 1987;37:770-1.
12. Sava G, Pacor S, Zorzet S, Alessio E, Mestroni G. Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in the Lewis lung carcinoma system. Pharmacol Res 1989;21:617-28.
13. Fruhauf S, Zeller WJ. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells. Cancer Res 1991;51:2943-8.
14. Novakova O, Kasparkova J, Vrana O, van Vliet PM, Reedijk J, Brabec V. Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry 1995;34:12369-78.
15. Morris RE, Aird RE, Murdoch Pdel S, et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem2001;44:36 16-21.
16. Scolaro C, Bergamo A, Brescacin L, et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem 2005;48:41 61-71.
17. Depenbrock H, Schmelcher S, Peter R, et al. Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells. Eur J Cancer 1997;33:2404-10.
18. Bergamo A, Gava B, Alessio E, et al. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int J Oncol 2002;21:1331-8.
19. Cohen GL, Bauer WR, Barton JK, Lippard SJ. Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. Science 1979;203:1014-6.
20. Mei HY, Barton JK. Tris(tetramethylphenanthroline) ruthenium(II): a chiral probe that cleaves A-DNA conformations. Proc Natl Acad Sci U S A 1988;85:1339-43.
21. Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 2002;71:1-68.
22. Zeglis BM, Pierre VC, Barton JK. Metallo-intercalators and metallo-insertors. Chem Commun (Camb) 2007:4565-79.
23. Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP. Ruthenium(II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J Pharmacol Exp Ther 2005;315:1403-11.
24. Hayward RL, Schornagel QC, Tente R, et al. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175. Cancer Chemother Pharmacol 2005;55:577-83.
25. Chatterjee S, Kundu S, Bhattacharyya A, Hartinger CG, Dyson PJ. The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem2008;13:11 49-55.
26. Jakupec MA, Reisner E, Eichinger A, et al. Redoxactive antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J Med Chem2005;48:28 31-7.
27. Smalley KS, Contractor R, Haass NK, et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 2007;67:209-17.
28. Ang WH, De Luca A, Chapuis-Bernasconi C, Juillerat-Jeanneret L, Lo Bello M, Dyson PJ. Organometallic ruthenium inhibitors of glutathione -S-transferase P1-1 as anticancer drugs. ChemMedChem 2007.
29. Dougan SJ, Habtemariam A, McHale SE, Parsons S, Sadler PJ. Catalytic organometallic anticancer complexes. Proc Natl Acad Sci U S A 2008;105:11628-33.
30. Leyva L, Sirlin C, Rubio L, et al. Synthesis of cycloruthenated compounds as potential anticancer agents. Eur J Inorg Chem 2007:305 5-66.
31. Benosman S, Gross I, Clarke N, et al. Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis. Cell Death Differ 2007.
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
33. Gross I, Armant O, Benosman S, et al. Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death Differ 2007;14:1802-12.
34. Ord D, Ord T. Characterization of human NIPK (TRB3, SKIP3) gene activation in stressful conditions. Biochem Biophys Res Commun 2005;330:210-8.
35. Selim E, Frkanec JT, Cunard R. Fibrates upregulate TRB3 in lymphocytes independent of PPARα by augmenting CCAAT/enhancer-binding protein β (C/EBPβ) expression. Mol Immunol 2007;44:1218-29.
36. Ubeda M, Habener JF. CHOP transcription factor phosphorylation by casein kinase 2 inhibits transcriptional activation. J Biol Chem2003;278:4051 4-20.
37. Bruhat A, Jousse C, Carraro V, Reimold AM, Ferrara M, Fafournoux P. Amino acids control mammalian gene transcription: activating transcription factor 2 is essential for the amino acid responsiveness of the CHOP promoter. Mol Cell Biol 2000;20:7192-204.
38. Reimers K, Choi CY, Bucan V, Vogt PM. The Bax Inhibitor-1 (BI-1) family in apoptosis and tumorigenesis. Curr Mol Med 2008;8:148-56.
39. Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell death. Oncogene 2008;27:6507-21.
40. Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 2005;18:617-22.
41. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278:9100-6.
42. Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell 2002;3:99-111.
43. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007;8:519-29.
44. Marciniak SJ, Yun CY, Oyadomari S, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004;18:3066-77.
45. Zinszner H, Kuroda M, Wang X, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998;12:982-95.
46. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004;11:381-9.
47. Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ. CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-3-CHOP cascade. J Immunol 2009;182:466-76.
48. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage [see comments]. Nature 1999;399:806-9.
49. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002;4:865-70.
50. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.